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Abstract
ORALLY-DOSED CITALOPRAM STIMULATES SMALL INTESTINAL MUCOSAL
GROWTH
Lucy Zhang, Chasen J. Greig, and Robert A. Cowles. Section of Pediatric Surgery,
Department of Surgery, Yale University, School of Medicine, New Haven, CT, USA.

Parenterally-administered selective serotonin reuptake inhibitors (SSRI), such as
citalopram, increase intestinal mucosal absorptive surface by day 7 of treatment. We
hypothesized that enteral citalopram would also induce intestinal mucosal growth, thus
allowing for therapy with an oral agent. In the study’s first phase, C57BL/6 mice
received peanut butter (PB) pellets containing 10, 50, or 100 mg/kg/day citalopram for 7
days; or 25 mg/kg/day citalopram for 14 or 21 days; or plain PB pellets for 7, 14, or 21
days. In the second phase, C57BL/6 mice received 0, 10, 25, or 50 mg/kg/day
citalopram in drinking water for 2, 3, 6, or 8 weeks, or for 6 weeks followed by 2 weeks
of drug withdrawal. Two-centimeter ileal segments were harvested and prepared for
microscopic assessment of villus height (VH), crypt depth (CD), villus width (VW), and
crypt width (CW). Mucosal surface area (MSA) was calculated and data were compared
using Student’s t-test. Enteral citalopram given for 14 days in PB pellets resulted in an
increased VH (p <0.0001), VW (p = 0.0058), and ileal MSA per mm2 (p = 0.0007). The
increase in MSA was sustained at 21 days (p <0.0001). When citalopram was given in
drinking water, VH was greater than controls by week 3 (p <0.0001 across all three
doses); however, MSA per mm2 was not significantly increased, regardless of treatment
dose or duration. Further work is needed, but SSRIs show some promise in the shortterm period as oral therapy for serious intestinal disorders such as short bowel
syndrome.
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So find something new to try, something to change. Count how often you succeed and how often
you fail. Write about it. Ask people what they think. See if you can keep the conversation going.
—Atul Gawande, Better: A Surgeon’s Notes on Performance (1)
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Introduction
1.1.

Short Bowel Syndrome and Intestinal Failure

In 1968, Wilmore and Dudrick revolutionized the care of children with short bowel
syndrome (SBS) when they described the first such infant to grow and gain weight while
receiving only intravenous parenteral nutrition (PN) over the course of over 6 weeks (2).
She had undergone major bowel resection for intestinal atresia, and shortly after the
operation, developed a functional intestinal obstruction. Despite receiving intravenous
fluids containing plasma, glucose, and protein, she continued to lose significant weight
and deteriorate in condition. At that point, the decision was made to initiate PN. Within
24 hours, she was noticeably resuscitated, and by day 45, her remaining bowel had
adapted sufficiently to allow for tolerance of full enteral nutrition (2).
Fifty years later, PN remains a mainstay of SBS treatment, yet the outcomes are
poor. Any investigation into better treatments for SBS, however, first requires an
understanding of SBS.

1.1.1.

Definition and Epidemiology

SBS is characterized by malabsorption that stems from major loss of small intestinal
surface area, typically due to surgical resection or congenital disease, and can affect both
children and adults (3). The most common etiologies in the neonatal and young
pediatric populations are necrotizing enterocolitis and intestinal anomalies, such as
midgut volvulus, gastroschisis, Hirschsprung disease, and as Wilmore and Dudrick
encountered, intestinal atresia (3-5). Among older children and adults, SBS is more often
associated with Crohn disease, radiation, ischemia, trauma, and malignancy (3). In turn,
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SBS is the most common cause of intestinal failure (IF), which is a blanket term used to
describe a condition of grossly insufficient nutrient absorption resulting in not only an
inability to support homeostasis or growth, but also a dependence on PN. Causes of IF
that are not associated with shortened bowel length include disorders of intestinal
motility as well as congenital enteropathies (3, 6).
Given the lack of a consensus definition for SBS/IF, however, considerable
variability exists in the incidence of SBS/IF that is reported in the literature. One
retrospective cohort study found that, at their institution, the incidence of newborns
with SBS was 353.7 cases per 100,000 live births in preterm infants and 3.5 per 100,000 in
term infants, for an overall rate of 24.5/100,000 (3, 7). Other studies have found SBS
incidence rates of 700 and 1200 per 100,000 live births, among neonates weighing less
than 1500 grams (4, 6, 8, 9).
Despite many advances in treatment options over the past 50 years since PN was
introduced for SBS/IF, the outcomes are still devastating. Several factors, including
length of remaining small bowel (less than 50 cm), the absence of intact colon and/or
ileocecal valve, older patient age, and dependence on PN, portend a poorer prognosis.
Mortality rates range consistently from approximately 10% to 30% (4-6, 10-15).

1.1.2.

Economics

The economic impact of SBS/IF is almost as staggering. One study, adjusted for inflation
to the year 2005, found that the total cost of care for patients with SBS in the first five
years after diagnosis was on average more than 1.6 million US dollars, with the first year
typically costing a little over $500,000 and years 2-5 costing roughly $250,000 to $300,000
each year (5). Inpatient hospitalizations and readmissions accounted for the large
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majority of this cost, especially in the first few years after diagnosis. As the years went
by, patients spent progressively less and less time in the hospital, and this was reflected
in the costs of care: in-hospital expenses shrank from over $400,000 in the first year to
less than $50,000 in the fifth year, while home care costs more than doubled from less
than $90,000 in the first year to almost $185,000 by year 5 (5). PN was the predominant
home care expense, even as most patients were eventually able to wean off of it. The
categories of “antimicrobials,” “injectables,” “intravenous hydration,” and “enteral
nutrition” additionally contributed to home costs (5). These data clearly suggest that
SBS/IF is a costly and morbid disease that warrants aggressive study.

1.1.3.

Intestinal Adaptation and Complications

Much of the morbidity of SBS/IF derives from the disease process itself as well as
sequelae of the treatment, which begs the need for investigation into better treatment
options. In response to major resection, the intestine gradually undergoes changes to
compensate for the reduced absorptive surface and capacity. This process, termed
“intestinal adaptation,” includes gastric hypersecretion, small bowel dilatation, and, to
some extent, lengthening, as well as increases in villus height and crypt depth at the
microscopic level (6, 11, 12). These changes are thought to occur in an attempt to restore
mucosal surface area that was lost due to resection.
Fifty percent of patients who ultimately wean from PN to enteral autonomy do
so within the first 6 months, and 95% are able to be free from PN within 2 years (11, 13).
However, those most severely affected patients who require long-term PN, or those who
never successfully wean from PN, are at significant ongoing risk for several
complications.
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Malabsorptive diarrhea is one such symptom that plagues patients with SBS/IF,
and can precipitate fluid and electrolyte imbalances. Furthermore, the major resection of
small bowel prevents the absorption of vitamins and minerals, particularly vitamin B12,
zinc, magnesium, calcium, and the fat-soluble vitamins A, D, E, K, and has been shown
to remove an inhibitory mechanism and trigger hypergastrinemia, hyperacidity, and
peptic ulcer occurrence (4, 11). Ileal resection disrupts the enterohepatic circulation of
bile acids, which not only contributes to fat malabsorption and both secretory diarrhea
and steatorrhea in patients with SBS, but also cholelithiasis and calcium oxalate
nephrolithiasis (11).
Small intestinal bacterial overgrowth (SIBO) is another common consequence of
the changes in intestinal anatomy, motility, and secretion associated with SBS (6, 16). Of
note, the bacteria Lactobacilli can cause D-lactic acidosis in patients with an intact colon,
by fermenting carbohydrates into D-lactic acid, which is then absorbed in the colon. The
condition is characterized by mental status changes and an anion gap metabolic acidosis
that is unexplained because laboratory tests typically measure for the L-lactic acid
stereoisomer (11).
While myriad issues arise from the malabsorption and intestinal resection of
SBS/IF, another considerable set of complications stems from the use of PN. Central
venous access carries its own substantial risks: catheter breakage, thrombosis, infection,
and sepsis (4). Ethanol lock therapy, in which 70% ethanol is infused into the catheter
during off-cycles of PN, seems to be effective in reducing the number of central catheterassociated bloodstream infections; however, there is evidence to suggest that ethanol
may adversely affect the catheter material (silicone) and integrity (6, 17-19). Moreover,
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reduced bone mineral density and metabolic bone disease, in the form of osteomalacia
or osteoporosis, has been found in up to 84% of patients receiving PN (11, 20).
Arguably the most notorious and potentially fatal complication, however, is
intestinal failure-associated liver disease (IFALD). IFALD can lead to steatosis,
cholestasis, fibrosis, and even cirrhosis, and affects up to 40-60% of infants on PN (4, 11,
21-23). Furthermore, a strong correlation has been found between SBS mortality and
IFALD. One study found that Kaplan-Meier survival was less than 20% among children
with cholestasis; in those without cholestasis, survival was closer to 80% (4, 24). Thus,
minimizing the need for PN and maximizing functional intestinal surface area and
intestinal motility are important goals in the treatment of patients with SBS/IF.

1.1.4.

Treatment

Both SBS and IF are complex conditions that require long-term care from multiple
disciplines, whether nutritional, surgical, medical, or some combination of the three.
Notably, intestinal rehabilitation programs have been developed worldwide to more
easily coordinate care for these complex patients, and these efforts have been shown to
prolong survival (10, 25, 26). The various treatment options and approaches for patients
with SBS/IF are described below.

Nutritional Therapy
Much of the long-term management of fluid, electrolyte, and nutritional balance in
patients with SBS/IF is achieved through a combination of oral nutrition, enteral
nutrition, and PN. Nutritional needs are heavily dictated by which segments and what
lengths of bowel remain intact (4, 16, 26). For instance, in patients without a colon, small,
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frequent meals high in fat, soluble fiber, and complex carbohydrates are recommended.
Isotonic oral rehydration solutions (ORS) make use of the sodium-glucose cotransporter
in the small bowel and are therefore especially important in these patients for fluid
uptake and hydration (16, 26). In contrast, those individuals with intact colon are better
suited to diets of limited fat content and greater proportions of complex carbohydrates;
ORS are not necessary. Similarly, maintenance of vitamin B12 and methylmalonic acid
levels is especially important in cases of resection of the distal ileum (16, 26). It is
suggested that all patients with SBS take calcium, magnesium, and zinc supplements in
addition to a daily multivitamin. In those not receiving PN, supplementation with the
fat-soluble vitamins A, D, E, and K is encouraged (4, 16, 26).
Safe PN is life-saving for patients with SBS/IF. Recent advances in our
understanding of the relationship between PN and IFALD have shed some light on how
to best provide PN safely. PN preparations containing soy-derived omega-6 fatty acids
may play a role in IFALD. There have been preliminary reports to suggest that, in fact,
fish oil-based omega-3 fatty acids may be beneficial in pediatric IFALD (6, 11). For
example, Smoflipid (Fresenius Kabi), an intravenous fat emulsion containing fish, soy,
olive, and medium-chain oils, was approved in 2016 for adults. Thus far, one pediatric
randomized controlled trial has shown promising results: lower levels of conjugated
bilirubin were found in infants treated with Smoflipid as compared to those treated with
the soy-derived Intralipid (Fresenius Kabi) (6, 27). Further studies are needed, however,
as laboratory markers of cholestasis do not always correlate with liver histology (6).
Early enteral nutrition, whether via nasogastric/gastrostromy tube or by mouth,
has been shown to promote intestinal absorption and adaptation; the ability to wean
from PN and transition to enteral feeding is associated with higher rates of survival (4, 5,
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16). Ultimately, the ideal goal in patients with SBS/IF is enteral autonomy: growth and
maintenance of nutrition status and liver function, preferably without PN (4).

Surgical Therapy
Surgical procedures are a cornerstone of the management of patients with SBS. The
spectrum of available options includes the placement of central venous catheters to
deliver fluids and PN, as well as the insertion of gastrostomy, gastrojejunostomy, or
jejunostomy devices to facilitate continuous feedings and enteral nutrition (4, 6). Other
patients may be appropriate candidates for longitudinal intestinal lengthening and
tailoring (LILT), the serial transverse enteroplasty (STEP) procedure, or even intestinal
transplantation.
LILT was first introduced by Bianchi in 1980 (28). In the operation, the
mesenteric vasculature is carefully preserved before the intestinal lumen is divided
longitudinally in half with a gastrointestinal anastomosis (GIA) stapler. The two
“hemiloops” of bowel are then anastomosed end-to-end, to essentially double the
intestinal length (28).
In the STEP procedure, the GIA stapler is serially used on alternating sides of the
bowel, to create a zig-zag pattern. This method, which effectively narrows the bowel
lumen while increasing intestinal length, preserves the vasculature, avoids enterotomies
and anastomoses, and has been very successful (4, 29).
Lastly, intestinal transplantation is an option for patients with “permanent” IF
and critically serious PN complications: portal hypertension, impaired liver synthetic
function, numerous central line infections, multiple instances of central venous
thrombosis, and recurrent severe dehydration (4). Though five-year survival rates are
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approximately 50%, the one-year rates range from 80% to over 90%, far surpassing the
60% of patients who survive five years on PN. Taking into consideration the high cost of
PN, the value of intestinal transplantation in patients with permanent IF has become a
matter of small debate (4).

Pharmacotherapy
The pharmacotherapy for SBS is largely limited to antisecretory and antimotility agents,
as well as agents thought to promote intestinal growth and adaptation (12, 16, 26).
Therapies targeting the gastric hypersecretion and secretory diarrhea that commonly ail
patients with SBS include H2 blockers, proton-pump inhibitors, octreotide,
cholestyramine, and the α2 agonist clonidine (4, 16, 26, 30-32). Similarly, antimotility
medications such as loperamide, diphenoxylate/atropine, and certain opioids (codeine,
opium tincture) have been shown to provide relief and help slow intestinal transit time
(4, 16, 26). Unfortunately, these therapies have been primarily studied in adult SBS/IF
patients; few have been explored in the pediatric population (6).
Various other treatments have found utility in SBS. Broad-spectrum antibiotics,
namely metronidazole, ciprofloxacin, and rifaximin, and probiotics have been used to
combat small intestinal bacterial overgrowth (6, 16, 26). Ursodeoxycholic acid has also
been effective in managing PN-associated cholestasis (4).
One of the most notable pharmacotherapies for SBS available to date, however, is
teduglutide, a glucagon-like peptide 2 analog. Administered via subcutaneous injection,
it is currently approved for adult PN-dependent patients, but its propensity to stimulate
the development of neoplasms has limited its use, especially in children (33). Thus, there
are no approved therapies for children that specifically aim to increase intestinal surface
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area and absorptive function. For these reasons, new therapies that specifically and
actively increase intestinal mucosal surface area, especially those administered orally,
are desperately needed for children with severe SBS and IF.

1.2.

Serotonin and the Enteric Nervous System

The neural crest gives rise to the enteric nervous system (ENS), which is a complex
network of nerves found in the bowel wall extending from the esophagus to the anus. It
is comprised of the myenteric and submucosal plexuses. The ENS notably functions and
carries out reflexes independently of the central nervous system (CNS), but nevertheless,
there is much interaction between the two nervous systems (34, 35).
Indeed, one of the most well-known neurotransmitters in the brain, serotonin or
5-hydroxytryptamine (5-HT), is also found in great abundance in the ENS. Its receptors
and functions are found in every major organ system in the body, but in fact, an
overwhelming 95% of the body’s 5-HT stores are found in the gastrointestinal (GI)
system (35, 36). Serotonin’s synthesis occurs in enterochromaffin cells of the intestinal
mucosa, where it then acts on extrinsic nerves involved in sensory neurotransmission to
the CNS, 5-HT3 receptors of intrinsic primary afferent neurons (IPANs) in the myenteric
plexus, and 5-HT1P receptors of IPANs in the submucosal plexus. Aided by 5-HT4,
submucosal nerves release acetylcholine and calcitonin gene-related peptide (CGRP),
which ultimately influence intestinal secretion and peristalsis. Myenteric IPANs release
only acetylcholine and have been implicated in giant migrating contractions (35). There
has also been evidence to show that serotonin plays a role in bone formation and liver
regeneration, as well as in enteric neurogenesis (35, 37-39).
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The ubiquity of 5-HT in the bowel and the ability of the ENS to control multiple
aspects of GI function drove us to explore serotonin’s potential as an intestinal mucosal
growth factor, with the ultimate goal of targeting the 5-HT signaling system as a therapy
for SBS/IF.

1.2.1.

Previous Work

Due to the distribution of serotonin and the availability of pharmacologic agents that
have been designed to alter its physiology, we have focused on its action in the bowel.
Our laboratory has shown previously, via both genetic knock-out models and
pharmacologic inhibition, that neuronal serotonin induces intestinal mucosal growth
(40). In these experiments, wild-type (WT) mice receiving selective serotonin reuptake
inhibitors (SSRIs) parenterally via intraperitoneally implanted osmotic micropumps
were found to have increased villus height (VH), crypt depth (CD), and enterocyte
proliferation, by day 7 of treatment (40). We therefore aimed to extend these findings to
allow for a more translational approach and hypothesized that enteral dosing of the
SSRI citalopram would also induce intestinal mucosal growth, thus allowing for therapy
with a commonly available oral agent.
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Statement of Purpose
Specific Aims:
1. To develop an enteral route of administering SSRI to mice in a reliable, safe, and
palatable manner.
2. To examine the effect of enteral citalopram on intestinal mucosal growth in WT
mice.

Hypothesis:
1. The enteral administration of citalopram is strongly associated with increases in
VH and CD in WT mice in a dose- and time-dependent fashion, when compared
to WT mice that do not receive SSRI.
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Methods
This protocol (#2016-11567) was approved by the Yale University Institutional Animal
Care & Use Committee.

3.1.

Author Contributions

All data acquisition (animal experiments, intestinal resection, morphometric
measurements), statistical analysis, and data interpretation were completed by LZ. All
authors (LZ, CJG, RAC) participated in the conception and design of the study as well as
drafting and critical revision of the associated manuscript.

3.2.

Vehicle of SSRI Administration

Our experiments were conducted in two phases. In the first, we opted to use peanut
butter (PB) as the vehicle of drug delivery, in lieu of more stressful approaches such as
oral gavage, and adapted our methods from previously described studies (41, 42). For
our second phase of longer-term studies, we explored the administration of SSRI in
drinking water. Both methods of SSRI administration are described below in greater
detail.

3.2.1.

Peanut Butter Pellets

Peanut Delight creamy PB (Aldi Inc., Batavia, IL, USA) was heated in an 850-watt
microwave oven for 40-80 seconds until a thick liquid consistency was achieved. PB
pellets with SSRI were prepared by thoroughly mixing citalopram hydrobromide
(Tokyo Chemical Industry Co., Ltd., Tokyo, Japan; Acros Organics, New Jersey, USA) at
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10, 25, 50, or 100 mg/kg per 0.2 mL pellet into the PB. All pellets were aliquoted onto a
Parafilm membrane using a small-volume syringe, then stored for use at -20°C. Fresh
pellets were made every 4-5 days (Figure 1). Mice underwent a 7-day habituation period
and then either a 7-, 14-, or 21-day experimental period. Throughout both phases, they
were transferred temporarily to individual cages for the duration of the administration
of the PB pellet.

Figure 1. Peanut Butter (PB) Pellets.

Habituation Period
Every day for seven consecutive days, mice were presented with a 0.2 mL plain PB pellet
that was placed on the nozzle of a water bottle. Mice did not immediately take to the PB
pellet—perhaps due to its novelty—but as described in the literature, by day 7, they
consumed it within minutes of presentation (41).

Experimental Period
One cohort of mice was fed PB pellets containing either 10 mg/kg, 50 mg/kg, or 100
mg/kg citalopram, or plain PB pellets, once daily for 7 days. Significant difficulty was
noted in ensuring that mice consumed the PB pellets with the higher doses of
citalopram, and therefore a more modest dose of drug was chosen for additional
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experiments. The second cohort was provided with pellets containing 25 mg/kg
citalopram or plain PB pellets, once daily for 14 or 21 days. Pellets were again presented
via water bottle nozzle and mice consumed these without difficulty.

3.2.2.

Drinking Water

In order to more feasibly conduct longer term studies, we used drinking water as a
vehicle of delivery of enteral SSRI. Given that mice take in anywhere between 2.12 mL
and 6.7 mL of water per day, we assumed a daily average of 4 mL water (43, 44).
Solutions of citalopram hydrobromide were prepared at concentrations of 10, 25, or 50
mg/kg/day; dissolved into tap water by vortexing; and administered for 2, 3, 6, or 8
weeks, or for 6 weeks immediately followed by 2 weeks of plain tap water. Opaque
water bottles were used throughout all drinking water experiments in order to protect
both drug and water from light, and fresh solutions were made weekly.

3.3.

Animals

The average mouse lives for 1 to 3 years. Weaning occurs at age 3-4 weeks, and puberty
at 4-7 weeks (43). We chose to utilize 6- to 10-week old mice as our model of the
pediatric age group.
Wild-type C57BL/6 mice were housed with access to standard chow and water
ad libitum under standard 12 hour light/dark conditions in the Yale Animal Resource
Center. For the entire duration of our experiments, mice were weighed daily (PB pellet
studies) or weekly (drinking water studies). One mouse, of all animals studied in both
the PB pellet and drinking water studies, was euthanized due to illness prior to the end
of the experimental period. In order to reduce bias and facilitate investigator blinding,
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all animals and subsequent tissue specimens and histologic slides were each identified
by a nondescript cage number and ear clipping; the treatment condition assigned to each
mouse was referred to only when absolutely necessary during treatment (PB pellet or
water bottle) administration.

3.4.

Histology

At the conclusion of the experimental period, mice were euthanized by CO2
asphyxiation. A midline laparotomy was performed, and the small intestine was
isolated, harvested, and gently flushed free of stool with 10% neutral buffered formalin
(NBF). Two-centimeter segments of the distal ileum were fixed overnight at room
temperature in 10% NBF. We enlisted the help of Yale Pathology Tissue Services to
paraffin-embed and section the tissue specimens into thin slices for staining with
hematoxylin and eosin. Lastly, the slides were visualized under standard brightfield
microscopy at 20x magnification (Zeiss Axio Imager.M1, Oberkochen, Germany).

3.5.

Measurements and Calculations

Using ImageJ (NIH, Bethesda, MD, USA), we measured VH, CD, villus width (VW), and
crypt width (CW), as defined by the crypt-villus junction (Figure 2).
As detailed above, investigators carrying out the measurements were blind to the
experimental treatment condition corresponding to each histologic slide. Intestinal villi
and crypts selected for measurement were unique and fully intact with the entire length
of the central lacteal or crypt lumen clearly visible. We did not measure villi or crypts
that had evidence of damage, artifact from histological preparation, or oblique
sectioning (45).
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Figure 2. Example Villus Unit with
Corresponding Villus and Crypt.
VH = villus height, VW = villus
width, CD = crypt depth, CW = crypt
width.

Figure 2 demonstrates a representative villus unit. For each villus unit with
corresponding values for VH, VW, CD, and CW, we used a previously described
mathematical approximation of intestinal mucosal surface area (MSA) to calculate MSA
per mm2 (46):

MSA per mm2 =

VW CW 2
+ 2 )
2
VW CW 2
( 2 + 2 )

(VW×VH) + (

VW 2

−( 2 )

(46)

All measured and calculated data were compared using Student’s t-test. Statistical
significance was defined when p <0.05.
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Results
Treatment with oral citalopram caused no obvious adverse effects. SSRI-treated animals
experienced similar patterns of weight gain—and namely, did not experience weight
loss—when compared to control animals.

4.1.

Peanut Butter Pellets

Seven days of oral citalopram given at 10, 50, or 100 mg/kg/day resulted in virtually no
differences compared to controls treated with PB pellets alone in three of the measured
parameters, VH, VW, and CD, regardless of citalopram dose; the one exception was an
increase in VW (p = 0.0093) in mice receiving 10 mg/kg/day. At all three doses,
however, CW decreased significantly (p-values ranging from 0.0002 to <0.0001), likely
contributing to the increases in MSA (p-values from 0.0578 to 0.0006) (Table 1).

Table 1. Measured Mucosal Parameters after the Enteral Administration of
Citalopram in Peanut Butter (PB) Pellets for 7 Days.
Vehicle (n)

10 mg/kg/day (n) p-value 50 mg/kg/day (n) p-value 100 mg/kg/day (n) p-value

VH (μm)

209.7 ± 5.8 (40) 210.6 ± 2.6 (103) 0.8703

217.9 ± 4.4 (34) 0.2774

198.7 ± 3.4 (63)

0.0829

VW (μm)

58.8 ± 1.7 (40)

63.8 ± 0.9 (103) 0.0093

57.0 ± 2.2 (34) 0.5119

62.2 ± 1.2 (63)

0.1124

CD (μm)

69.8 ± 8.0 (6)

82.0 ± 2.4 (52)

0.1138

74.5 ± 2.6 (22) 0.4718

70.9 ± 3.0 (26)

0.8855

CW (μm)

46.4 ± 2.2 (6)

33.0 ± 0.7 (52) <0.0001

36.3 ± 1.0 (22) 0.0002

35.2 ± 0.8 (26)

<0.0001

MSA (per mm2)

5.2 ± 0.1 (6)

6.4 ± 0.1 (52)

6.3 ± 0.1 (22)

5.8 ± 0.2 (26)

0.0578

0.0045

0.0006

VH = villus height, VW = villus width, CD = crypt depth, CW = crypt width, MSA =
mucosal surface area

After 14 days of treatment, enteral citalopram at 25 mg/kg/day significantly
increased VH and VW compared to controls, by approximately 12.3% (p <0.0001) and
12.2% (p = 0.0058), respectively. CD remained statistically similar (p = 0.2960), and CW
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decreased by 12.7% (p = 0.0020). Overall, calculated ileal MSA per mm2 increased by
22% from 5.0 ± 0.2 to 6.1 ± 0.1 (p = 0.0007) (Figure 3).
Significant differences in VH, VW (data not shown), and CD were no longer seen
by day 21 of enteral citalopram at 25 mg/kg/day. Crypt width decreased by 37.7% (p
<0.0001), with a concurrent increase in MSA of 36.8% (p <0.0001) (Figure 3).

Figure 3. Measured Mucosal Parameters after the Enteral Administration of
Citalopram in Peanut Butter (PB) Pellets for 14 or 21 Days.
Citalopram was dosed at 25 mg/kg/day. Panels A-D show VH, CD, CW, and MSA,
respectively. VH = villus height, CD = crypt depth, CW = crypt width, MSA = mucosal
surface area. * denotes p <0.05.
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4.2.

Drinking Water

Citalopram was administered in drinking water at 10, 25, or 50 mg/kg per day, for 2, 3,
6, or 8 weeks; Figure 4 depicts MSA per square millimeter under these experimental
conditions. Notably, with one exception at week 2 (Table 2), no differences in MSA were
seen until week 6 when comparing controls and the three treatment doses. At the 6week and 8-week time points, mucosal surface was consistently greater in controls than
in any animals receiving enteral citalopram (p <0.0001 across all doses at both time
points).

Figure 4. Mucosal Surface Area (MSA) after Long-Term Enteral Administration of
Citalopram.

In mice that received citalopram-treated drinking water of 10 or 50 mg/kg/day
for 2 weeks, VH decreased from controls by 7.3% (p = 0.0016) and 13.7% (p <0.0001),
respectively, while in those that received 25 mg/kg/day citalopram, VH remained
statistically similar (p = 0.6394). CD was significantly reduced among all animals given
citalopram in water for 2 weeks (p <0.0001 across all three doses). The only change in
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MSA per mm2 for this treatment duration, a reduction from 5.5 ± 0.2 in controls to 4.6 ±
0.1 (p = 0.0006), occurred at a drug concentration of 50 mg/kg/day.
By 3 weeks, citalopram-treated villi were taller than controls by roughly 32.9%
(10 mg/kg/day, p <0.0001), 28.3% (25 mg/kg/day, p <0.0001), and 13.8% (50
mg/kg/day, p <0.0001). No differences, however, were seen in CW (p = 0.8309, p =
0.1231, and p = 0.1394, corresponding respectively to 10, 25, and 50 mg/kg/day
citalopram) or MSA (p = 0.2053, p = 0.1628, and p = 0.3609).
VH was increased from controls by 3.1% after treatment with 10 mg/kg/day
citalopram for 6 weeks (p = 0.0308); dosing at 50 mg/kg/day resulted in an 11.5%
increase (p <0.0001). A 4.4% reduction in height was seen with the 25 mg/kg/day dose
(p = 0.0057) (Figure 5). Furthermore, after 6 weeks, all villi and crypts of citalopramtreated mice were significantly wider than controls, while crypt depth was decreased.
As noted above, calculated mucosal surface by week 6 in animals of the three treatment
doses was 20.6%, 25.4%, and 14.3% less than that of controls (corresponding to 10, 25,
and 50 mg/kg/day citalopram, respectively; p <0.0001 across all three doses).

Figure 5. Villus Height (VH) after Administration of Citalopram in Drinking Water.
Panels A and B correspond to 6- and 8-week treatments, respectively.
* denotes p <0.05
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The time point at 8 weeks was notable for shorter and wider villi in all
citalopram-treated animals when compared to controls (p <0.0001 across all three doses,
for both VH and VW) (Figure 5). Again, MSA per mm2 in animals receiving 10, 25, or 50
mg/kg/day citalopram in water for 8 weeks was decreased from controls by 25.4%,
28.2%, and 26.8%, respectively (p <0.0001 across all three doses).
Drug withdrawal for 2 weeks following 6 weeks of citalopram treatment also
showed villi that were significantly shorter and wider than controls. While CW was
statistically similar between control and all treatment groups in this cohort, MSA per
mm2 in treated animals was reduced from controls by 21.1%, 33.8%, and 31.0%
(respectively 10, 25, and 50 mg/kg/day citalopram; p <0.0001 across all three doses).
Mean values for VH, VW, CD, CW, and MSA under all experimental doses and
durations are detailed in Table 2.
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Table 2. Measured Mucosal Parameters after the Enteral Administration of
Citalopram in Drinking Water.
Treatment for 2 Weeks
Vehicle (n)

10 mg/kg/day (n) p-value 25 mg/kg/day (n) p-value 50 mg/kg/day (n) p-value

VH (μm)

206.3 ± 6.3 (30) 191.2 ± 1.3 (351) 0.0016 209.3 ± 2.4 (174) 0.6394 178.0 ± 1.6 (295) <0.0001

VW (μm)

68.8 ± 1.6 (30)

65.3 ± 0.5 (351) 0.0616

63.5 ± 0.6 (174) 0.0012

CD (μm)

97.0 ± 2.2 (18)

75.2 ± 2.1 (116) <0.0001

67.8 ± 3.6 (49) <0.0001 63.1 ± 1.1 (103) <0.0001

CW (μm)

36.4 ± 1.1 (18)

39.3 ± 0.8 (116) 0.1362

41.3 ± 0.7 (49)

0.0004

5.6 ± 0.1 (52)

0.9475

MSA (per mm2)

5.5 ± 0.2 (8)

5.3 ± 0.1 (97)

0.5155

65.5 ± 0.6 (295) 0.0707
43.0 ± 0.5 (103) <0.0001
4.6 ± 0.1 (71)

0.0006

Treatment for 3 Weeks
Vehicle (n)

10 mg/kg/day (n) p-value 25 mg/kg/day (n) p-value 50 mg/kg/day (n) p-value

VH (μm)

153.9 ± 6.7 (14) 204.5 ± 1.6 (234) <0.0001 197.5 ± 2.0 (203) <0.0001 175.2 ± 1.0 (342) <0.0001

VW (μm)

73.5 ± 3.2 (14)

70.2 ± 0.8 (234) 0.3306

65.4 ± 0.7 (203) 0.0064

64.4 ± 0.5 (342) 0.0002

CD (μm)

89.0 ± 4.1 (6)

76.6 ± 1.8 (100) 0.1027

69.8 ± 2.5 (68)

0.0278

53.3 ± 0.9 (89) <0.0001

CW (μm)

42.1 ± 2.8 (6)

42.8 ± 0.8 (100) 0.8309

38.0 ± 0.7 (68)

0.1231

39.0 ± 0.5 (89)

0.1394

5.4 ± 0.1 (53)

0.1628

4.8 ± 0.1 (79)

0.3609

MSA (per

mm2)

4.4 ± 0.3 (2)

5.2 ± 0.1 (60)

0.2053

Treatment for 6 Weeks
Vehicle (n)

10 mg/kg/day (n) p-value 25 mg/kg/day (n) p-value 50 mg/kg/day (n) p-value

VH (μm)

182.5 ± 2.5 (125) 188.1 ± 1.3 (285) 0.0308 174.5 ± 1.6 (286) 0.0057 203.4 ± 1.7 (193) <0.0001

VW (μm)

52.8 ± 0.7 (125)

63.7 ± 0.5 (285) <0.0001 67.8 ± 0.5 (286) <0.0001 62.9 ± 0.7 (193) <0.0001

CD (μm)

68.8 ± 1.4 (68)

61.2 ± 1.3 (82)

29.4 ± 0.6 (68)

40.9 ± 0.7 (82) <0.0001

41.6 ± 0.5 (96) <0.0001

41.5 ± 0.6 (77) <0.0001

6.3 ± 0.2 (49)

5.0 ± 0.1 (52)

4.7 ± 0.1 (70)

5.4 ± 0.1 (44)

CW (μm)
MSA (per

mm2)

0.0001
<0.0001

62.3 ± 1.2 (96)

0.0006
<0.0001

62.1 ± 1.7 (77)

0.0032
<0.0001

Treatment for 8 Weeks
Vehicle (n)

10 mg/kg/day (n) p-value 25 mg/kg/day (n) p-value 50 mg/kg/day (n) p-value

VH (μm)

239.5 ± 7.1 (39) 207.4 ± 2.3 (221) <0.0001 206.6 ± 2.3 (224) <0.0001 190.5 ± 2.4 (163) <0.0001

VW (μm)

56.2 ± 1.8 (39)

66.5 ± 0.7 (221) <0.0001 67.2 ± 0.8 (224) <0.0001 63.4 ± 0.6 (163) <0.0001

CD (μm)

69.3 ± 4.0 (9)

71.5 ± 1.2 (102) 0.5897

68.9 ± 1.6 (80)

CW (μm)

39.7 ± 2.1 (9)

42.7 ± 0.5 (102) 0.0774

MSA (per mm2) 7.1 ± 0.4 (12)

5.3 ± 0.1 (60)

<0.0001

0.9353

54.9 ± 0.9 (68) <0.0001

44.4 ± 0.7 (80)

0.0451

40.0 ± 0.7 (68)

0.8856

5.1 ± 0.1 (49)

<0.0001

5.2 ± 0.1 (46)

<0.0001

Treatment for 6 Weeks + Withdrawal for 2 Weeks
Vehicle (n)

10 mg/kg/day (n) p-value 25 mg/kg/day (n) p-value 50 mg/kg/day (n) p-value

VH (μm)

239.5 ± 7.1 (39) 220.3 ± 2.5 (142) 0.0017 176.4 ± 2.5 (293) <0.0001 181.2 ± 2.1 (321) <0.0001

VW (μm)

56.2 ± 1.8 (39)

67.8 ± 0.9 (142) <0.0001 70.2 ± 0.6 (293) <0.0001 66.0 ± 0.7 (321) <0.0001

CD (μm)

69.3 ± 4.0 (9)

72.3 ± 1.2 (72)

0.4099

67.1 ± 2.1 (98)

0.7645

60.7 ± 1.3 (84)

0.0461

CW (μm)

39.7 ± 2.1 (9)

43.6 ± 0.7 (72)

0.0777

42.3 ± 0.6 (98)

0.1986

42.6 ± 0.9 (84)

0.2915

7.1 ± 0.4 (12)

5.6 ± 0.1 (50)

<0.0001

4.7 ± 0.1 (81)

<0.0001

4.9 ± 0.1 (64)

<0.0001

MSA (per

mm2)
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Discussion
In previous work, we studied VH and CD, among other parameters, after parenteral
administration of citalopram at 25 mg/kg/day. By 7 and 14 days of treatment, VH was
increased from controls by roughly 15% and 12%, respectively, and CD by 7% and 18%
(40). That same investigation examined genetic mouse models where the serotonin
reuptake transporter is absent (SERTKO), and found an increase in VH by
approximately 40% compared to WT mice (40).
Building on this past work, in the first phase of the current study, we delivered
citalopram via PB pellets to WT mice for 7, 14, or 21 days, at varying doses. No changes
in either VH or CD were seen when citalopram was given for 7 days, at 3 doses ranging
from 10 to 100 mg/kg/day. On the other hand, fourteen days of citalopram in PB pellets
at 25 mg/kg/day caused a statistically significant increase in VH of approximately 12%,
though CD remained unchanged compared to controls. The slower changes seen with
this enteral route of administration of SSRI are most likely pharmacokinetic in nature
and secondary to first-pass metabolism, which is not involved when the drug is given
parenterally (47, 48). Our findings also suggest that changes in CD may be slowest to
occur, if at all, of all measured parameters.
In the second phase of our study, citalopram was delivered in drinking water for
2, 3, 6, or 8 weeks, as well as for 6 weeks immediately followed by a 2-week washout
period. In contrast to the findings seen with citalopram in PB pellets, dosing of the drug
in drinking water resulted in taller villi by three, not two, weeks. As we expected both
PB pellets and drinking water to be comparable enteral routes of administration, this
result was somewhat surprising. One explanation may lie in the difference between the
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bolus-style drug delivery of PB pellets and relatively continuous drug supply of
drinking water. Moreover, although mice had unlimited access to their water treatment,
we had assumed an average daily water intake of 4 mL, and they were otherwise
relatively unmonitored in the animal housing facility. It is very possible that the
citalopram water was poorly palatable, that mice drank less water than assumed, and
that steady-state drug levels were low. Overall, we did not monitor daily water intake or
citalopram levels in the body at any point during the study.
Another unexpected finding was that all doses and durations of the citalopramtreated water showed either no difference in MSA from controls, or in some cases, a
significant decrease. Most notably, mucosal surface in the control group progressively
increased from week 3 to week 6 to week 8, as the animal grew in age and size. This
trend was not seen in any of the experimental groups, raising the question of an
inhibitory effect with chronic treatment. By comparison, 25 mg/kg/day citalopram in
PB pellets increased mucosal surface per mm2 by 21.8% by week 2 and by 36.8% by week
3. It is perhaps worth noting, however, that VH, VW, and CD, were statistically similar
between the PB experimental and control groups at the 3-week mark; narrower crypts,
and not taller, thinner villi or deeper crypts, were the most likely driver of the increases
in MSA in that cohort.
One group of mice received citalopram in drinking water for six weeks, and then
was immediately transitioned to plain tap water for two weeks. Comparison with the 8week control group showed shorter, wider villi, corresponding to a decreased MSA per
mm2. These trends were identical to those observed in the 8-week experimental group,
suggesting that citalopram’s effects on intestinal mucosal morphology may begin to
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plateau at the 6- to 8-week mark, or that it may simply take longer than two weeks for
the mucosa to return to its starting baseline.
With respect to currently available medical therapies for SBS, teduglutide
remains the only one approved for use in adult disease. In the study demonstrating
efficacy of this agent, mice injected with glucagon-like peptide 2 were found to have
increases in VH, from controls, of approximately 25% by 6 days of treatment and 50% by
10 days, with no significant differences in CD (49). By contrast, we found that 14 days of
enteral citalopram resulted in a more modest increase in VH of 12.3%. Whether this is a
mechanistic and/or pharmacokinetic phenomenon remains to be seen; nevertheless, the
oral route of citalopram administration was associated with a concurrent increase in VW
and decrease in CW, likely contributing to the 22% increase in calculated MSA.
Many questions remain regarding the precise role that serotonin plays in the
ENS in the maintenance of intestinal mucosa, as well as the implications of intestinal
mucosal growth on intestinal function. While further work is needed to refine our
current understanding of this complex signaling environment in the ENS, we have
presented some data to demonstrate the potential efficacy of an orally administered SSRI
to promote intestinal mucosal growth, especially in the short-term period.

5.1.

Future Directions

Long-term parenteral studies would provide invaluable data to compare with the results
presented here. Further avenues of investigation into the enteral route should include
analysis of other segments of the small bowel, such as the jejunum, as well as other
measures of intestinal mucosal growth, such as intestinal weight and the crypt
proliferation index (a marker of cell division). Given that the palatability of citalopram
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may be a limiting factor, future work should also explore other methods of enteral
delivery, such as oral gavage, to ensure that the drug is ingested fully and in the
expected amounts. While we have preliminary data showing increased absorption of
solutes and nutrients in genetic mouse models, functional assays in the setting of enteral
SSRI treatment would be of great interest. The ultimate goal would be to examine
enteral SSRI administration in a large animal model of intestinal injury or after massive
resection.
The population of patients who have short bowel syndrome and are also
prescribed SSRIs for a mood disorder may prove to be enlightening. In 2014, Faye et al.
examined the pharmacokinetics of oral and intravenous citalopram or escitalopram in
eight such patients (50). Though the authors’ focus was primarily on steady-state
concentrations and concentration-dose ratios (CDRs), they also included in their analysis
such variables as frequency of PN, small bowel length, and percentage of intact colon.
Patients required PN anywhere from 0 to 7 times per week, and their remaining lengths
of small intestine ranged from 5 cm to 200 cm. A small intestinal length of less than 20
cm was associated with poor absorption (low steady-state concentration and CDR),
while patients with greater than 180 cm of small bowel remaining, or more than 80 cm
small bowel and at least half their colon, had normal serum levels of drug (50). While
this was a small study, it introduces a special group of patients who are highly relevant
to the research question posed here.

5.2.

Limitations

Though both plain and SSRI PB pellets were indistinguishable in appearance,
investigators were not blinded to the type of pellet they administered. Higher doses of
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citalopram were not as readily accepted by mice when presented as part of a PB pellet,
and the final dose absorbed by each animal was difficult to control entirely when
compared to a parenteral dosing regimen. Similarly, investigators were not blinded to
the drug concentration when preparing, refilling, and administering citalopram
solutions.
Moreover, the sample sizes of the drinking water control groups (that is, no
drug) were very small. Only one animal was studied per experimental condition, which
therefore limited the number of intact villi and crypts that were candidates for
measurement. Additionally, both male and female mice were used indiscriminately
throughout the study, as well as mice anywhere from 6 to 10 weeks of age. Our study
did not control or balance for sex, as recommended in 2014 by the National Institutes of
Health’s “Policy on Sex as a Biological Variable” (51, 52). These potentially confounding
factors, in addition to random variation itself, could have been mitigated with a more
robust sample size.
To truly isolate the effect of citalopram, it would have been ideal to measure villi
and crypts before and after drug treatment from the same animal. Lastly, the equation
we favored to estimate mucosal surface area is merely one of several mathematical
models that have been proposed (46, 53, 54).

5.3.

Conclusions

This year, 2018, marks 50 years since Wilmore and Dudrick first used parenteral
nutrition to treat pediatric short bowel syndrome. Though we now have a great number
more and a wider variety of treatment options for SBS and IF, PN remains fundamental
to management of these patients, and the outcomes are still devastating.
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Building on previous work on parenteral citalopram, we sought to investigate
the effect of the enteral citalopram on intestinal mucosal morphometrics and surface
area in WT mice, at a range of treatment doses and durations. In this study, we utilized
both PB pellets and drinking water as vehicles to deliver our drug. Fourteen days of
citalopram in PB pellets resulted in increased VH, VW, and ileal MSA, and the increased
mucosal surface was sustained at day 21. Drinking water seemed to be less effective. VH
in citalopram-treated animals was greater than controls by week 3, but this finding
dissipated by weeks 6 and 8. MSA per mm2 in the treatment group, across all doses and
durations, was statistically similar to or decreased from the control group.
While the drinking water results were unexpected, much of the PB pellet data
showed promise. Further studies would be invaluable for shedding light on the
serotonin signaling system in the bowel, as well as on the potential for an orally and
commonly available agent to treat serious intestinal disorders such as short bowel
syndrome.
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